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ABSTRACT
Introduction Several licensed and investigational 
vaccines have lower efficacy, and induce impaired immune 
responses, in low- income versus high- income countries 
and in rural, versus urban, settings. Understanding these 
population differences is essential to optimising vaccine 
effectiveness in the tropics. We suggest that repeated 
exposure to and immunomodulation by chronic helminth 
infections partly explains population differences in vaccine 
response.
Methods and analysis We have designed an individually 
randomised, parallel group trial of intensive versus 
standard praziquantel (PZQ) intervention against 
schistosomiasis, to determine effects on vaccine response 
outcomes among school- going adolescents (9–17 years) 
from rural Schistosoma mansoni- endemic Ugandan 
islands. Vaccines to be studied comprise BCG on day 
‘zero’; yellow fever, oral typhoid and human papilloma 
virus (HPV) vaccines at week 4; and HPV and tetanus/
diphtheria booster vaccine at week 28. The intensive arm 
will receive PZQ doses three times, each 2 weeks apart, 
before BCG immunisation, followed by a dose at week 8 
and quarterly thereafter. The standard arm will receive PZQ 
at week 8 and 52. We expect to enrol 480 participants, 
with 80% infected with S. mansoni at the outset.
Primary outcomes are BCG- specific interferon-γ ELISpot 
responses 8 weeks after BCG immunisation and for other 
vaccines, antibody responses to key vaccine antigens 
at 4 weeks after immunisation. Secondary analyses will 
determine the effects of intensive anthelminthic treatment 
on correlates of protective immunity, on waning of vaccine 
response, on priming versus boosting immunisations and 
on S. mansoni infection status and intensity. Exploratory 
immunology assays using archived samples will enable 
assessment of mechanistic links between helminths and 
vaccine responses.
Ethics and dissemination Ethics approval has been 
obtained from relevant ethics committes of Uganda and 
UK. Results will be shared with Uganda Ministry of Health, 
relevant district councils, community leaders and study 
participants. Further dissemination will be done through 
conference proceedings and publications.
Trial registration number ISRCTN60517191.
Strengths and limitations of this study
 ► This will be the first adequately powered interven-
tion study to investigate the effects of schistosomi-
asis treatment on vaccine responses in adolescents.
 ► Effects on both live- attenuated and inert vaccines 
will be studied.
 ► Our strong immunoepidemiological design and nest-
ed immunological studies will address specific hy-
potheses regarding pathways of effects.
 ► The sample archives developed will provide a major 
asset for exploration of new leads arising from this 
hypothesis- driven work, or for an alternative, ‘sys-
tems biology’ approach investigating (for example) 
transcriptome, microbiome and virome.
 ► Even with intensive anthelminthic intervention, it 
may be difficult to ‘successfully’ treat Schistosoma 
infection in our endemic setting due to re- infections; 
however, we still expect a substantial difference in 
intensity between the two trial arms.
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INTRODUCTION
Vaccine- specific immune responses are often impaired, 
and vaccine efficacy and effectiveness lower, in tropical 
low- income countries compared with temperate high- 
income countries and in rural, compared with urban, LIC 
settings.1–8 This has been recognised for both live vaccines 
(such as BCG,2 3 5 9 polio1 and yellow fever (YF)4 vaccines) 
and non- live vaccines (such as influenza10 and tetanus).11 
Investigational malaria7 and viral- vectored tuberculosis6 
and Ebola12 vaccines are also affected. Previous expo-
sure to the target pathogen (or related organisms) may 
mask the benefit of the vaccine.13 14 However, prevaccina-
tion exposure does not explain why Ebola trial vaccine- 
specific responses differ between healthy adults in UK 
and Senegal,12 as the target organism is rare. Therefore, 
environmentally dependent mechanisms may play an 
important role.5
A long- held hypothesis is that parasites, particularly 
helminths, modulate vaccine responses through profound 
preimmunisation and postimmunisation bystander 
effects on immunological activation and regulation.15–17 
Helminths might also impact vaccine’s responses through 
interactions with the complex ecosystem of mammalian 
gut bacteria, fungi, protozoa and viruses (the ‘transk-
ingdom’ concept18 detailed elsewhere in this journal 
(bmjopen-2020–040425)). Helminth- induced gut 
mucosa damage, the associated translocation of microbial 
products into the systemic circulation19–21 and systemic 
immune activation or regulation mediated by microbial 
products might contribute to modulation of responses to 
vaccines and other infections.
Helminth- mediated modulation of vaccine responses 
has not been substantiated in human populations. No 
appropriately powered trials have been conducted to 
evaluate reversibility of their effects. In animal models, 
helminths generally impair priming and accelerate 
waning of vaccine responses, although effects vary with 
helminth species, vaccine type and the timing of infec-
tion and immunisation.22 Most observational studies 
in humans also suggest suppressed or biased responses 
during helminth infection, especially during systemic 
infections, such as schistosomiasis and the filariases. 
There is modest evidence that treating geohelminths in 
humans improves responses to BCG23 24 or oral cholera 
vaccine25 and we found that schistosomiasis treatment 
improved the measles- booster response in preschool chil-
dren.26 There is, therefore, a strong case for a compre-
hensive assessment of the effects of helminths and their 
treatment on vaccine responses.
The extent to which helminths and related ‘transk-
ingdom’ mediators causally and reversibly impact 
immunological characteristics associated with vaccine 
responses may best be determined by intervention 
studies. This trial protocol A of the ‘Population differ-
ences in vaccine responses’ programme (POPVAC A; 
Current Controlled Trials identifier: ISRCTN60517191) 
has been designed to evaluate the effect of Schistosoma 
mansoni and its treatment on vaccine responses. This 
study is one of three parallel trials whose designs and 
cross- cutting analyses are described separately in this 
journal (bmjopen-2020–040425, bmjopen-2020–040427 
and bmjopen-2020–040430).
Hypothesis
The overarching goal of the POPVAC programme is to 
understand population differences in vaccine responses 
in Uganda, in order to identify strategies through which 
vaccine effectiveness can be optimised for the low- income, 
tropical settings where they are especially needed. For 
this Trial A, we focus on the hypothesis that S. mansoni 
infection suppresses responses to unrelated vaccines; and 
that this effect can be reversed, at least in part, by inten-
sive praziquantel (PZQ) treatment intervention.
Objective
To determine whether there are reversible effects of 
chronic S. mansoni infection on vaccine response in 
adolescents, using an intervention study.
METHODS AND ANALYSIS
Setting and participants
Standard Protocol Items: Recommendations for Interven-
tional Trials reporting guidelines27 have been used. We 
will conduct an individually randomised, parallel group 
trial of intensive versus standard intervention against 
schistosomiasis (described below) in the S. mansoni- 
endemic Koome islands of Lake Victoria, Mukono district, 
Uganda.28 We aim to enrol 480 participants, randomising 
240 to each intervention arm. The study cohort will recruit 
participants aged 9–17 years in primary school years 1–6. 
Adolescents29 in this study setting bear a heavy parasite 
burden.30 In addition, this age group is a target group for 
vaccines against sexually transmitted infections (currently 
human papilloma virus (HPV); in future, it is hoped, for 
vaccines against HIV) and for booster immunisations.
Recruitment criteria
Inclusion criteria
1. Attending the selected school and planning to contin-
ue to attend the school for the duration of the study.
2. Aged 9–17 years and enrolled in primary 1–6 (to avoid 
primary leaving examinations in late year 7, and loss to 
follow- up of children leaving after primary 7).
3. Written informed assent by participant and consent by 
parent or guardian.
4. Females agreeing to avoid pregnancy for the duration 
of the trial.
5. Willing to provide locator information and to be con-
tacted during the course of the trial.
6. Able and willing (in the investigator’s opinion) to com-
ply with all the study requirements.
Exclusion criteria
1. Clinically significant history of immunodeficien-
cy (including HIV), cancer, cardiovascular disease, 
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gastrointestinal disease, liver disease, renal disease, 
endocrine disorder and neurological illness.
2. History of serious psychiatric condition or disorder.
3. Moderate or severe acute illness characterised by any 
of the following symptoms: fever, impaired conscious-
ness, convulsions, difficulty in breathing or vomiting; 
or as otherwise determined by the attending project 
clinician.
4. Concurrent oral or systemic steroid medication or 
the concurrent use of other immunosuppressive 
agents within 2 months prior to enrolment.
5. History of allergic reaction to immunisation or any 
allergy likely to be exacerbated by any component of 
the study vaccines, including egg or chicken proteins.
6. History of previous immunisation with YF, oral ty-
phoid or HPV vaccine; previous immunisation with 
BCG or tetanus and diphtheria vaccine (Td) at age 
≥5 years.
7. Tendency to develop keloid scars.
8. Haemoglobin less than 82 g/L.
9. Positive HIV serology.
10. Positive pregnancy test.
11. Female currently lactating, confirmed pregnancy or 
intention to become pregnant during the trial period.
12. Use of an investigational medicinal product or non- 
registered drug, live vaccine or medical device other 
than the study vaccines for 30 days prior to dosing 
with the study vaccine, or planned use during the 
study period.
13. Administration of immunoglobulins and/or any 
blood products within the 3 months preceding the 
planned trial immunisation date.
Further information on recruitment criteria can be 
found in online supplemental file 1.
Interventions
We will individually randomise participants to intensive 
or standard PZQ treatment in a 1:1 ratio. The intensive 
arm will receive three doses of PZQ (approximately 40 
mg/kg, assessed by height pole31) each 2 weeks apart 
prior to the first immunisation (the last of these 2–3 
weeks before immunisation), followed by PZQ at 8 
weeks (after primary endpoint sampling) and there-
after quarterly PZQ (approximately; timings adjusted 
to accommodate school terms) during follow- up. The 
standard arm will receive their first dose of PZQ at 
week 8 (after immunisation and after primary endpoint 
sampling) and a second dose at week 52 (to conform 
to Uganda Ministry of Health policy, which is annual 
treatment) (figure 1). No placebo will be used in this 
trial because all participants will be treated (although 
at different frequencies) and participants are unlikely 
to seek additional treatments outside the trial schedule: 
PZQ treatment is not popular because of the recognised 
(although temporary) adverse effects (described in 
online supplemental file 1).
Randomisation and allocation to treatment arm
A randomisation code will be generated by an indepen-
dent statistician using a randomly permuted block size 
(sizes 4, 6, 8 and 10) and used to allocate participants to 
either receive quarterly PZQ (intensive arm) or annual 
PZQ (standard arm). A set of envelopes will be prepared, 
labelled sequentially with the randomisation numbers 
and containing a card indicating the corresponding 
allocation (to intensive or standard treatment). The 
randomisation code will be kept securely by the trial stat-
istician and made available only to those responsible for 
providing or preparing the trial interventions. A second 
copy will be held by a data manager or statistician not 
otherwise involved in the trial at the Medical Research 
Council/Uganda Virus Research Institute and London 
School of Hygiene and Tropical Medicine (MRC/UVRI 
and LSHTM) Uganda Research Unit. At enrolment, eligi-
bility criteria will be checked and eligible participants 
will be allocated sequentially to the next randomisa-
tion number until the required sample size is achieved. 
Randomisation implementation will be done by a clini-
cian using the sequentially numbered opaque sealed 
envelopes. When the next randomisation number in the 
sequence is allocated, the envelope bearing that number 
will be opened to reveal the allocation.
Blinding
Clinicians and participants will not be blinded to the treat-
ment allocation since they will not participate in outcome 
ascertainment; only immunology laboratory staff who are 
assessing trial outcomes will be blinded.
Immunisations
We will study a portfolio of licensed vaccines (live and 
inert, oral and parental, priming and boosting) expected 
to be beneficial (in some cases, already given) to adoles-
cents in Uganda. Our schedule (table 1 and online supple-
mental table S1) will comprise three main immunisation 
days (weeks 0, 4 and 28). Additional HPV immunisation 
will be provided for girls aged 14 years or above, and a 
Figure 1 Outline of immunisations and anthelminthic 
intervention.1Primary endpoints will be at 8 weeks post BCG 
and 4 weeks post yellow fever (YF- 17D), oral typhoid (Ty21a), 
human papilloma virus (HPV) and tetanus/diptheria (Td) 
vaccination.2Primary endpoint for responses to Td given at 
28 weeks.
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second Td boost will be given after completion of the 
study, to accord with the national Expanded Programme 
on Immunisation (EPI) routines, but the response to 
these will not specifically be assessed. Further rationale 
for the selection of vaccines is detailed in the online 
supplemental file 1.
Schedule of immunisation and sampling
The schedule of immunisation and sampling is outlined 
in figure 1 and online supplemental table S1. Pre- 
immunisation vaccine responses will be assessed in 
baseline samples. While optimal timings for outcome 
measures vary between vaccines, sampling at 8 weeks 
post BCG and 4 weeks post YF- 17D, Ty21a, HPV and Td is 
proposed for the primary endpoints, targeting the estab-
lishment of memory responses and approximate peak of 
antibody responses. A secondary endpoint at 1 year will 
assess waning. Immunisation postponement criteria are 
detailed in online supplemental file 1.
Outcomes
Primary outcomes
These will be assessed in all participants.
1. BCG: BCG- specific interferon (IFN)-γ ELISpot re-
sponse 8 weeks post BCG immunisation.
2. YF- 17D: neutralising antibody titres (plaque- reduction 
neutralisation test) at 4 weeks post YF immunisation.
3. Ty21a: Salmonella typhi lipopolysaccharide- specific IgG 
concentration at 4 weeks post Ty21a immunisation.
4. HPV: IgG specific for L1- proteins of HPV-16/18 at 4 
weeks post HPV priming immunisation.
5. Td: Tetanus and diphtheria toxoid- specific IgG con-
centration at 4 weeks post Td immunisation.
Secondary outcomes
These will be assessed in all participants and will further 
investigate estimates of protective immunity (for vaccines 
where these are available) and dynamics of the vaccine 
responses, as well as the impact of the interventions on 
parasite clearance.
1. Protective immunity. Proportions with protective neu-
tralising antibody (YF); protective IgG levels (Tetanus 
toxoid);32 and seroconversion rates (Ty21a) at 4 weeks 
post the corresponding immunisation.
2. Response waning. Primary outcome measures (all vac-
cines) repeated at week 52, and area- under- the curve 
analyses. Parasitic infection may accelerate,33 and anti- 
parasitic interventions delay, waning.
3. Priming versus boosting. Effects on priming versus 
boosting will be examined for HPV only, comparing 
outcomes 4 weeks after the first, and 4 weeks after the 
second vaccine dose.
4. Current S. mansoni infection status and intensity will be 
determined by serum/plasma levels of circulating an-
odic antigen (CAA). The method is quantitative, high-
ly specific for Schistosoma infection, and much more 
sensitive than the conventional Kato Katz method.34 
CAA will be assessed retrospectively on stored samples 
collected at baseline, on immunisation days, and on 
primary and secondary endpoint days.
Furthermore, our sample collection will offer oppor-
tunities for an array of exploratory immunological eval-
uations on stored samples, focusing mainly on vaccine 
antigen- specific outcomes. Exploratory assays will provide 
further detail on the role of immunological profiles and 
transkingdom effects in mediating helminth modulation 
of vaccine- specific responses.
Evaluation of parasite infection exposure
The following measures will also be assessed in all partici-
pants, and will be used to describe the general infection–
exposure experience of the study participants.
1. Prior exposure to schistosomiasis will be evaluated by 
ELISA for IgG to schistosome egg antigen using stored 
blood samples collected at baseline.
2. The presence of other helminth infections will be de-
termined retrospectively using stool PCR of samples 
collected at baseline and at weeks 28 and 52.30 In ac-
cordance with national guidelines, all participants will 
be treated with albendazole or mebendazole after col-
lection of samples for primary endpoints at weeks 8 
and 28, and after collection of samples for secondary 
endpoints at week 52.












Live vaccines BCG vaccination/re- 
vaccination*
Yellow fever (YF- 17D)
Oral typhoid (Ty21a)
      
Non- live vaccines   HPV prime† HPV boost for girls 




*Prior BCG status may vary (data on history and documentation of prior BCG, and presence of a BCG scar, will be documented although 
these approaches have limitations for determining BCG status).
†Both girls and boys will receive the HPV vaccine.
‡The National Expanded Programme on Immunisation recommends three doses of HPV vaccine for older girls.
§These doses will be given to comply with guidelines but outcomes specifically relating to these doses will not be assessed.
¶Priming by immunisation in infancy is assumed.
HPV, human papilloma virus; Td, tetanus/ diphtheria.
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3. Current malaria infection status and intensity will be 
assessed retrospectively by PCR on stored samples col-
lected on immunisation days and at week 52. Individ-
uals presenting with fever will be investigated using 
rapid diagnostic tests for malaria and treated based on 
the results and according to prevailing national guide-
lines.
4. Prior malaria exposure will be evaluated by ELISA for 
IgG to malaria antigen using stored samples collected 
at baseline.
Sample size considerations
Based on the literature4 35 36 and preliminary data, we 
anticipate that, following log10 transformations that will 
be applied to normalise primary outcome measures, SDs 
of primary outcome measures will lie between 0.3 and 0.6 
on this log scale, and that effective treatment may increase 
responses by approximately 0.2 on the log scale (based 
on Tweyongyere et al.26 We have, therefore, powered our 
study to detect differences of this magnitude (0.2 on the 
log scale) or (in some cases) smaller (table 2). We assume 
S. mansoni prevalence of ≥80%.
Based on these assumptions and a two independent 
samples t- test, we plan to include 480 participants in total 
(240 quarterly PZQ and 240 annual PZQ); of whom 384 
are expected to be S. mansoni infected,28 giving 192 partic-
ipants in each trial arm who are infected at baseline.
Table 2 shows power estimates, for 5% type 1 error rate 
for each primary outcome measure and assuming 20% 
loss to follow- up.
Ethics and dissemination
Ethical approval has been granted from the Research 
Ethics Committee of the UVRI Regional Ethics Committee 
(REC; reference: GC/127/19/05/664) and the London 
School of Hygiene and Tropical Medicine (LSHTM, refer-
ence: 16032), and from the Uganda National Council for 
Science and Technology (UNCST, reference: HS2486) 
and the Uganda National Drug Authority (NDA, refer-
ence: CTA0093). Any protocol amendments will be 
submitted to ethics committees and regulatory bodies for 
approval before implementation.
Participants are adolescents and, therefore, a vulner-
able human population. Care will be taken to provide 
adequate, age and education- status appropriate informa-
tion and to ensure that it is understood; and to empha-
sise that participation is voluntary. Participants will be 
enrolled only when they have given their own assent and 
when consent has been given by the parent or guardian. 
Model consent and assent forms are shown in online 
supplemental file 2. No major risks to the participants 
are anticipated since all the treatments and vaccines to 
be given are licensed and known to be safe. The main risk 
to participants will be time lost from school work: we will 
work with teachers and parents to minimise disruption to 
classes, and will avoid enrolment of primary 7 students, 
since these classes are involved in national examinations. 
Further risks are discussed in online supplemental file 1.
Study findings will be published through open access 
peer- reviewed journals, presentations at local, national 
and international conferences and to the local commu-
nity through community meetings. Anonymised partici-
pant level data sets generated will be available on request.
Patient and public involvement
Concepts involved in this work have been discussed with 
colleagues at the Vector Control Division and EPI in the 
Ministry of Health (Uganda), with the Mukono District 
Council and with community leaders and village health 
teams from Koome subcounty. We also have held meet-
ings to explain the proposed work to teachers, parents, 
participants and village members, and to address their 
questions about issues, such as study length, the study’s 
ethical approval status, why adults were excluded from 
the study and to explain to them why boys will also receive 
the HPV vaccine. Study findings will be shared with these 
stakeholders and with participants.
Data management and analysis
Sociodemographic information and clinical and labo-
ratory measurements will be recorded and managed 
using Research Electronic Data Capture (REDCap) 
tools,37 38 with paper- based forms as backup. All data will 
be recorded under a unique study identifier number. 
When paper forms must be used, data will be double 
Table 2 Power estimates (5% type 1 error rate for each primary outcome measure)
Standard deviation (log10)
Difference in mean log10 transformed outcome between trial arms
0.08 0.10 0.12 0.14 0.16 0.18 0.20
192 intensive PZQ vs 192 standard PZQ (Schistosoma mansoni infected only)
0.3 65% 83% 94% 98% >99% >99% >99%
0.4 42% 59% 75% 87% 94% 98% 99%
0.5 29% 42% 56% 69% 80% 88% 94%
0.6 21% 31% 42% 53% 65% 75% 83%
Cells highlighted in grey correspond to >80% power; differences in mean log10 transformed outcome of 0.08, 0.10, 0.12, 0.14, 0.16, 0.18 and 
0.20 are equivalent to geometric mean ratios for untransformed outcomes of 1.20, 1.26, 1.32, 1.38, 1.45, 1.51 and 1.59, respectively.
PZQ, praziquantel .
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entered in a study- specific database, with standard checks 
for discrepancies. All data for analysis will be anonymised 
and stored on a secure and password- protected server, 
with access limited to essential research personnel.
Baseline characteristics including age, sex, school, loca-
tion of birth, prior vaccination status, helminth infection 
and prior exposure status and malaria infection and prior 
exposure status will be summarised by trial arm. The 
effect of intensive (compared with standard) PZQ treat-
ment on the outcomes will be analysed. Information on 
infection status will only be available after randomisation. 
The primary analysis will be done on individuals iden-
tified as infected at baseline (through randomisation, 
these will be balanced between treatment arms); this 
will test the hypothesis that treating the infection (and 
subsequent reinfections) reverses the parasite’s effects 
on vaccine responses. If treating S. mansoni reverses 
adverse parasite effects on vaccine responses, this may 
be a beneficial public health intervention. However, 
routine screening for parasite infection before immunisa-
tion would be laborious. Secondary analyses will include 
all randomised individuals; this will provide insight into 
the broader benefit of the interventions as public health 
measures. The effect of intensive versus standard PZQ 
treatment on primary outcomes will be assessed using 
unpaired t- tests, with results presented as a mean differ-
ence in vaccine response measure together with 95% 
CI and p value. For all outcomes, we will investigate 
adjusting for corresponding baseline vaccine responses 
as this may improve the precision of effect estimates; this 
will be done using multivariable regression. We anticipate 
that outcomes will be positively skewed, and will apply log 
transformations to normalise distributions before analysis 
if required. The detailed analytical plan is available on 
the online trial registration site (http://www. isrctn. com/ 
ISRCTN60517191).
DISCUSSION
This will be the first adequately powered intervention 
study to investigate the effect of schistosomiasis treatment 
on vaccine responses in adolescents. This study will deter-
mine whether S. mansoni infection has a causal, reversible 
impact on the response to live or inert vaccines, including 
effects on vaccine replication, immune response profile, 
priming, boosting and waning. The results will add to 
understanding of population differences in vaccine 
responses and on interventions that may enhance 
responses. If treating helminths improves vaccine 
responses in adolescents, combined parasite- control/
immunisation programmes offer an attractive, practical 
public health intervention for schools and communities.
There are risks associated with our approach to 
addressing the trial objective. First, there is a risk of failure 
to clear S. mansoni infections, and repeated reinfection 
during the trial. This issue can be challenging because 
of incomplete cure or maturation of immature worms 
after treatment, and lifestyles in endemic communities 
that result in repeated exposure. To mitigate this, we will 
administer three PZQ treatments over a 6- week period 
before the first immunisations, and continuing quarterly 
treatment in the intensive arm. Second, there is a risk that 
S. mansoni infection has long- term effects, not removed 
by treatment, and mediated, for example, by epigenetic 
change.39 However, studies show that parasite treatment 
results in immunological changes,40 41 and our data 
suggest at least partial recovery of the measles vaccine 
response among young children treated for schistosomi-
asis.26 By initiating intervention 6–8 weeks before the first 
immunisation, and providing repeated intervention in 
the intensive arms, we hope to achieve significant resolu-
tion of S. mansoni effects.
We are interested in the effects of removing S. mansoni. 
Treating parasites can induce acute immunological 
change due to release of previously hidden antigens.42 43 
To minimise such effects, immunisations will be given at 
least 2 weeks after PZQ (the longest practicable interval; 
figure 1).
Laboratory analyses will also highlight immune param-
eters and cellular populations that link environmental 
exposures to vaccine responses. Identifying processes 
associated with poor or good outcomes will inform strat-
egies in vaccine design (for example, the genetic modi-
fication of vaccines, or innovative use of adjuvants to 
counter any adverse immunological milieu, currently an 
area of intense research for cancer vaccines44); ultimately 
supporting the development of effective vaccines tailored 
to the low- income settings that most need them.
Study timeline
Applications for ethical approval were submitted in May 
2018, with approval received in September 2018 (UVRI 
REC), May 2019 (NDA and UNCST), June 2019 (LSHTM). 
Collaborator/investigator/trial steering committee meet-
ings were also held during the initial 12- month planning 
period. The study began recruitment in July 2019. Inter-
vention will be up to 12 months, with completion of the 
project scheduled for September 2020.
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